| 3OG7: reference: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma., Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K, Nature. 2010 Sep 7. PMID: 20823850 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).